<DOC>
	<DOCNO>NCT01555138</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety indacaterol salmeterol /fluticasone propionate treatment patient moderate chronic obstructive pulmonary disease , entry study treat salmeterol /fluticasone propionate .</brief_summary>
	<brief_title>Comparison Indacaterol 150 mcg Once Daily ( o.d . ) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily ( b.i.d . )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Patients moderate COPD ( Stage II ) Able perform spirometry assessment Current exsmokers On treatment fixeddose combination salmeterol 50 µg/fluticasone propionate 500 µg MDDPI b.i.d . treatment COPD ≥ 3 month directly precede Visit 1 . Having COPD exacerbation require treatment antibiotic and/or oral corticosteroid and/or hospitalization past year . Having history , current ECG abnormality Asthma Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>Salmeterol/fluticasone propionate</keyword>
</DOC>